In a report released yesterday, Joseph Schwartz from Leerink Partners maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), ...

Equities research analysts at Cantor Fitzgerald increased their FY2024 earnings estimates for PTC Therapeutics in a report ...

William Blair increased their FY2024 earnings estimates for PTC Therapeutics in a report issued on Monday, January 13th.

Cantor Fitzgerald lowered the firm’s price target on PTC Therapeutics (PTCT) to $76 from $80 and keeps an Overweight rating on the shares. The ...

PTC Therapeutics, Inc. (NASDAQ:PTCT), a biopharmaceutical company focused on developing and commercializing novel medicines for rare disorders, stands at a critical juncture as it navigates a year ...

PTC Therapeutics has demonstrated strong financial performance in recent quarters, consistently beating revenue expectations. In the third quarter of 2024, the company reported a total revenue beat of ...

Gabrielle White has been appointed as president of the Irish Exporters Association, the organisation said on Thursday. She ...

Check the time stamp on this data. Updated AI-Generated Signals for Ptc Therapeutics Inc. (PTCT) available here: PTCT. Type a ...

More than two years after its approval in Europe, PTC Therapeutics' gene therapy for rare genetic disorder AADC deficiency will soon be made available to patients in the US. The FDA has approved ...

The Irish Exporters Association has appointed Gabrielle White as its new President. Ms White is Executive Director, Head of ...

Novartis has made a dramatic return to the Huntington's disease therapy stage by licensing a candidate from PTC Therapeutics for a whopping $1 billion upfront. The deal – which has a potential ...